NIH trial: Gilead's drug works best in COVID patients on oxygen

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

from Reuters: Health News https://ift.tt/2AUmDCd
via IFTTT